Biomarker for diagnosing white matter lesion and application thereof

Abstract

The invention provides a biomarker for diagnosing white matter lesion and application thereof. The biomarker is cholesterol-alpha-D-glucoside. The biomarker cholesterol-alpha-D-glucoside is combined with 6Z,9Z,20-eicosatrienoic acid, ceramide (m18:1(4E) / 24:1(15Z)), ephedrine A, cucurbitacine E, cholesteryl ester 22:6 or ceramide (d18:0 / 24:1(15Z)) to judge whether white matter lesion exists or not. The biomarker for diagnosing the white matter lesion is used for preparing a detection reagent for diagnosing the white matter lesion, and is beneficial for diagnosing whether the white matter lesion tends to exist or not and preventing the white matter lesion in advance.

Description

technical field [0001] The invention belongs to the technical field of biological detection, and in particular relates to a biomarker for diagnosing cerebral white matter lesions and an application thereof. Background technique [0002] White matter lesion (WML) is a common neurodegenerative disease, the most typical pathological manifestations are damage to the integrity of white matter or demyelination, which is common in stroke, Alzheimer's disease, Parkinson's disease, multiple sclerosis, schizophrenia and many other diseases. White matter is an important part of the central nervous system, where nerve fibers gather. Damage to the myelin sheath of central nerve cells in white matter can cause white matter lesions. The typical response of white matter to various harmful stimuli is demyelination, which can be a secondary manifestation of neurological diseases such as infection, poisoning, degeneration, trauma, and lack of infarction. White matter lesions mainly cause sym...

AI Technical Summary

Problems solved by technology

However, it is unclear which substance can be clearly detected as the prediction and diagnosis of white matter lesions.

Images